Europe (AGES, Austria) Inspection of Shilpa Biologicals Pvt Ltd

Shilpa Medicare's Biologics arm Shilpa Biologics site at Dharwad, Karnataka, has received its European GMP certification for manufacturing of test batches based on the inspection between 18 Feb to 20 Feb 2025, conducted by the competent authority of Austria. The inspection covering the sterile drug product filling and packaging line, quality systems and quality control laboratories concluded compliance with the principles and guidelines of Good Manufacturing Practice laid down in Directive (EU) 2017/1572.

Dr. Sridevi Khambhampaty, CEO of Shilpa Biologics commented "This inspection outcome affirms our commitment to global quality standards and assures reliable outcomes for our customers."

Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 630.70 as compared to the previous close of Rs. 646.20. The total number of shares traded during the day was 6365 in over 563 trades.

The stock hit an intraday high of Rs. 654.75 and intraday low of 628.40. The net turnover during the day was Rs. 4053823.00.

Source : Equity Bulls

Keywords

ShilpaMedicare INE790G01031 Pharmaceuticals ShilpaBiologics AGES Austria EuropeanGMPCertification Dharwad